Progyny stock has climbed 40.3% over the past year, and investors now face a clear split between valuation signals, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to around 50% upside while market multiples suggest the shares screen as expensive.

• Over the last 12 months, Progyny has delivered a 40.3% return, which puts more pressure on today’s buyers to judge whether that performance already reflects the good news in the price.
• Recent analyst upgrades tied to stronger operating trends can support higher intrinsic value expectations. However, the market may reassess Progyny quickly if growth or spending plans fall short of what is currently implied.
• The company scores 3 out of 6 on valuation checks, a mixed picture that sits between a clear bargain and a clear overvaluation.

The issue now is whether Progyny's recent rerating leaves enough upside in the intrinsic value case to justify what earnings multiples are already asking investors to pay.

Does Progyny Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model looks at the cash Progyny can generate in the future and adjusts it back to today’s dollars. For Progyny, the latest twelve month free cash flow is about $194.7 million, and the model assumes these cash flows continue growing rather than swinging sharply up or down. Feeding those projections into a 2 Stage Free Cash Flow to Equity framework produces an estimated intrinsic value of about $64 per share.

Compared with the current share price, that intrinsic value suggests Progyny stock screens roughly 50.0% undervalued on this cash flow view. The recent analyst upgrades highlight stronger June activity and earnings momentum, and in that context the DCF result indicates the market price may not fully reflect the cash the business is expected to generate based on these projections.

On this analysis, Progyny stock appears undervalued relative to what its projected cash flows support.

Our Discounted Cash Flow (DCF) analysis suggests Progyny is undervalued by 50.0%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Is Progyny Getting Expensive on Earnings?

P/E is a useful check for Progyny because it ties the current share price directly to the earnings that support it. Progyny trades on a P/E of about 37.3x, which sits above the broader Healthcare sector average of roughly 25.7x and only slightly below a peer group average of about 39.6x.

A tailored model that looks at Progyny's growth profile, margins, size and risk suggests a fair P/E closer to 28.9x. That is a clear gap to the current 37.3x, indicating investors are already paying a premium relative to what those fundamentals support, even before considering any further good news. On this metric, the recent enthusiasm around Progyny is already well reflected in the valuation, which may leave less room for disappointment if expectations reset.

Overall, Progyny stock currently appears overvalued on its P/E multiple compared with the level implied by these fundamentals.

The Progyny Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Progyny pick up where this valuation puzzle leaves off by setting out the specific assumptions about Progyny's future growth, margins and earnings that would need to play out for the stock to be worth materially more or less than its current price, and they sit within the company’s Community page. Where a single ratio or model gives you one number, Narratives unpack the future behind that number so you can see which moving parts to watch over time.

Community narratives on Progyny sit far apart, with one group seeing untapped upside and another focused on valuation and execution risk.

Bull case: 8% undervalued

"The newly established strategic presence with Amazon's Health Benefits Connector, along with data-driven partnerships such as Oura, could accelerate direct-to-member brand awareness and inbound enrollment..."

Bear case: 8% overvalued

"Broad-based cost containment efforts and benefit prioritization by employers, especially in uncertain macroeconomic environments, may limit the uptake or expansion of premium fertility, maternity, and women's health benefits..."

Do you think there's more to the story for Progyny? Head over to our Community to see what others are saying!

The Bottom Line

For Progyny, the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while the current P/E suggests the stock already trades at a premium to what its fundamentals imply. That split reflects a cash flow view that is comfortable with the current funding needs and timing of returns, versus a multiples view that questions how much more growth and sentiment can lift the earnings base.

With broader valuation checks sitting in the middle, the key issue from here is whether Progyny can deliver the growth and margin profile that justifies both its intrinsic value estimate and its elevated earnings multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.